UBE2I (Ubc9) [untagged]

Ubiquigent

Catalog No: UBI-62-0034-020

Click here to view the Ubiquigent^TM Product Dashboard and hundreds of great reagents for ubiquitin-proteasome-related research.

Customer Notice Regarding Orders for Ubiquigent Products: From September 2020, orders for Ubiquigent products must total at least $700 to enable prompt delivery. Orders less than this amount may be subject to unpredictable wait times. Please contact us for further details.

Species Reactivity: Human  
Source: E. coli expression  
Formula: 50 mM HEPES pH 7.5, 150 mM sodium chloride, 2 mM dithiothreitol, 10% glycerol  
Concentration: 1 mg/ml  
Molecular Weight: ~18 kDa  
Protein Sequence: Accession number: NP_003336. For full protein sequence information download the Certificate of Analysis pdf.  
Quality Control Protein Identification: Confirmed by mass spectrometry.  
Quality Control Activity: SUMO-E2 Thioester Loading Assay: The activity of UBE2I was validated by loading E1 SAE1/SAE2 activated SUMO onto the active cysteine of the UBE2I E2 enzyme via a transthiolation reaction. Incubation of the SAE1/SAE2 and UBE2I enzymes in the presence of SUMO and ATP at 30 °C was compared at two time points, T0 and T10 minutes. Sensitivity of the SUMO/UBE2I thioester bond to the reducing agent DTT was confirmed.   

Background

The enzymes of the SUMOylation pathway play a pivotal role in a number of cellular processes including nuclear transport, signal transduction, stress responses and cell cycle progression. Covalent modification of proteins by small ubiquitin-related modifiers (SUMOs) may modulate their stability and subcellular compartmentalisation. Three classes of enzymes are involved in the process of SUMOylation; an activating enzyme (E1), conjugating enzyme (E2) and protein ligases (E3s). UBE2I is a member of the E2 conjugating enzyme family and cloning of the human gene was first described by Wang et al. (1996). The human UBE2I cDNA contains 7 exons sharing 56% and 100% identity with the yeast and mouse homologues respectively (Nacerddine et al., 2005; Shi et al., 2000; Wang et al., 1996). The candidate tumour suppressor gene Fragile Histidine Triad (FHIT) located on 3p14.2 is deleted in many types of human cancer. UBE2I binds to FHIT and this interaction is thought to be involved in the degradation of S and M phase cyclins and cell cycle control. Proliferating Cell Nuclear Antigen (PCNA) a DNA polymerase sliding clamp involved in DNA synthesis and repair is a substrate for UBE2I. SUMOylation of PCNA is mediated by UBE2I and occurs on a specific lysine residue – K146 – which may also be modified by ubiquitin (Hoege et al., 2002). Crystallography has revealed that UBE2I forms part of a four protein complex consisting of a NUP358/RANBP2 E3 ligase domain, and SUMO1 conjugated to the carboxy-terminal domain of RANGAP1. A model for the complex has been proposed in which NUP358/RANBP2 acts as an E3 by binding both SUMO and UBE2I to position the SUMO-E2-thioester in an optimal orientation to enhance conjugation (Reverter and Lima, 2005). SUMOylation of Amyloid Precursor Protein (APP) was reported to be associated with decreased levels of beta amyloid (Abeta) aggregates, suggesting a role in the pathogenesis of Alzheimer’s Disease (AD). An investigation into single nucleotide polymorphisms (SNPs) in the UBE2I gene have shown an association between this and the risk of late onset AD (Ahn et al., 2009).

References:

Ahn K, Song JH, Kim DK, Park MH, Jo SA, Koh YH (2009) Ubc9 gene polymorphisms and late-onset Alzheimer’s disease in the Korean population: a genetic association study. Neurosci Lett 465, 272-5.
Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S (2002) RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135-41.
Nacerddine K, Lehembre F, Bhaumik M, Artus J, Cohen-Tannoudji M, Babinet C, Pandolfi PP, Dejean A (2005) The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 9, 769-79.
Reverter D, Lima CD (2005) Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435, 687-92.
Shi Y, Zou M, Farid NR, Paterson MC (2000) Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem J 352 Pt 2, 443-8.
Wang ZY, Qiu QQ, Seufert W, Taguchi T, Testa JR, Whitmore SA, Callen DF, Welsh D, Shenk T, Deuel TF (1996) Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9. J Biol Chem 271, 24811-6.